The Unexpected Amplifiers: How Rethinking Growth Factors Could Reshape Cancer Treatment
The pursuit of understanding why things happen, not just that they happen, is a cornerstone of scientific progress. This principle, championed by Wendie Cohick, Vice Provost and Vice Chancellor for Research at Rutgers-New Brunswick, has not only earned her recognition as a 2026 Fellow of the American Association for the Advancement of Science (AAAS) – alongside seven other Rutgers faculty – but also quietly reshaped our understanding of fundamental biological processes. The recent announcement, made on March 26th by the world’s largest multidisciplinary scientific society, isn’t simply an acknowledgement of past achievements; it highlights a methodology increasingly vital in an era of increasingly complex biological questions. While headlines celebrate the honor bestowed upon these 500 scientists spanning 24 disciplines, the deeper story lies in the painstaking work of unraveling mechanisms, a process Cohick began decades ago with a simple question about dairy cows.
Original reporting: sebsnjaesnews.rutgers.edu.
Cohick’s journey began not with a grand hypothesis, but with observation. As an undergraduate at Cornell University, she found herself captivated by the unseen signals governing nutrient allocation in livestock – how a cow’s body prioritizes resources for fetal development or milk production. This curiosity led her to the then-nascent field of insulin-like growth factors (IGFs) in 1996, when she joined Rutgers’ School of Environmental and Biological Sciences. At the time, IGF-1 was recognized as crucial for growth and survival, but the intricate system regulating its activity remained largely unknown. The challenge wasn’t simply identifying the players, but understanding their interactions – a biological puzzle with most of the pieces still face down. This initial focus on agricultural science is critical to understanding the trajectory of her work; the scale and physiological demands of livestock provide a powerful model for studying fundamental growth processes.
The breakthrough came while studying mammary gland cells, where Cohick’s lab discovered a surprising role for one particular IGF binding protein. Contrary to prevailing assumptions, this protein didn’t dampen IGF-1’s effects, but actually amplified them, bolstering the hormone’s influence on cell growth. This finding wasn’t just a correction to the existing literature; it underscored Cohick’s core tenet: a thorough understanding of the underlying mechanism is paramount before attempting to manipulate a biological pathway. Intervening without this knowledge risks unintended consequences, potentially exacerbating the very problems one seeks to solve. This caution is particularly relevant in a field like cancer research, where interventions can have devastating side effects.
This mechanistic focus naturally extended Cohick’s research into human health, specifically breast cancer. Recognizing the “crosstalk” between hormone systems – the interplay between IGF-1 and estrogen, for example – she began investigating the potential link between early-life exposures, like alcohol consumption (a known risk factor for breast cancer due to its impact on estrogen levels), and long-term cancer risk. This concept of a “developmental window” – a period of heightened vulnerability to environmental influences – is gaining traction in public health, but Cohick’s work provides a crucial molecular framework for understanding how these early exposures might alter lifelong disease susceptibility. It’s a shift from simply identifying correlations to elucidating causal pathways.
Limitations to consider include the inherent challenges of translating findings from animal models to humans. While the physiological similarities between cows and humans are significant, subtle differences in hormone regulation and metabolic pathways could influence the effectiveness of interventions based on these findings. Furthermore, the complexity of human lifestyles and genetic diversity introduces additional layers of variability that are difficult to replicate in controlled laboratory settings. The AAAS fellowship recognizes not just the research itself, but the rigor with which it is conducted and the awareness of these inherent limitations.
Looking ahead, Cohick envisions a future of more precise, molecularly-guided cancer treatments. The goal isn’t simply to kill cancer cells, but to disrupt the specific pathways driving their growth, minimizing harm to healthy tissues. But the immediate next step isn’t necessarily a new drug; it’s a deeper understanding of the intricate signaling networks within cells. We should be watching for research that focuses on identifying biomarkers – measurable indicators of these pathways – that can predict an individual’s response to treatment. If we can identify patients whose tumors are particularly sensitive to IGF-1 signaling, for example, we can tailor therapies to maximize their effectiveness. The question now isn’t just whether we can target these pathways, but who will benefit most from doing so.
